Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 2:38 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1249–1272 of 1,569 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Control regimen Clear all

Conditions: Ventilator-associated Pneumonia
Interventions: Biotene OralBalance® gel, Sterile Water moisten cotton tipped applicator; Drug · Other
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 7 Days and older
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 2
States / cities: Winston-Salem, North Carolina

Conditions: Blood Flow Restriction, Growth Hormone, Strength Outcomes, Arginine
Interventions: BFR, Arginine, Placebo Pill; Procedure · Dietary Supplement
Lead sponsor: University of Mary Hardin-Baylor; Other
Eligibility: 18 Years to 25 Years · Female only
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Belton, Texas

Conditions: Type 1 Diabetes Mellitus
Interventions: Teplizumab, Placebo; Biological · Drug
Lead sponsor: MacroGenics; Industry
Eligibility: 8 Years to 35 Years
Enrollment: 554 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 39
States / cities: Birmingham, Alabama • Jonesboro, Arkansas • Little Rock, Arkansas + 36 more

Conditions: Hypertension
Interventions: Placebo, lorundrostat Dose 1, lorundrostat Dose 2; Drug
Lead sponsor: Mineralys Therapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 285 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 104
States / cities: Birmingham, Alabama • Chandler, Arizona • Mesa, Arizona + 88 more

Conditions: Oral Mucositis, Oral Cancer
Interventions: Oral Mucosa Deterging and Periodontal Debridement (OMDP), Standard of Care Oral Hygiene Instructions, Dental scaling, ultrasonic, Chlorhexidine; Procedure · Other
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: New York, New York

Conditions: Administration and Dosage of Ketamine, Endoscopic Sedation
Interventions: Ketamine, Midazolam injection, Fentanyl; Drug
Lead sponsor: Brooke Army Medical Center; Federal
Eligibility: 18 Years to 65 Years
Enrollment: 66 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Fort Sam Houston, Texas

Conditions: Breast Cancer
Interventions: MBSR(BC) 6 Week Program, BCES 6 Week Program; Behavioral
Lead sponsor: University of South Florida; Other
Eligibility: 21 Years and older · Female only
Enrollment: 214 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 5
States / cities: Sarasota, Florida • Tampa, Florida

Conditions: Respiratory Distress Syndrome, Newborn
Interventions: IV Atropine and Fentanyl Premedication Arm, IV Normal Saline Placebo Arm; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 0 Hours to 72 Hours
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: HIV Infections
Interventions: Cabotegravir Tablets, Cabotegravir Injectable Suspension (CAB LA), Rilpivirine Tablets, Rilpivirine Injectable Suspension (RPV LA), BIKTARVY Tablets (BIK); Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years and older
Enrollment: 687 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 41
States / cities: Bakersfield, California • Beverly Hills, California • Los Angeles, California + 32 more

Conditions: Acute Adenoviral Conjunctivitis
Interventions: FST-100 Ophthalmic Suspension, Placebo; Drug
Lead sponsor: Shire; Industry
Eligibility: 3 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 13
States / cities: Torrance, California • Colorado Springs, Colorado • Hamden, Connecticut + 10 more

Conditions: Diabetes Mellitus, Type 2
Interventions: Placebo, empagliflozin (low dose qd), Empagliflozin (high dose qd), empagliflozin (high dose bid), empagliflozin (low dose bid); Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 983 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 39
States / cities: Florence, Alabama • Jonesboro, Arkansas • Lomita, California + 34 more

Conditions: Lung Cancer
Interventions: Aerobic Training, Progressive Stretching, Resistance Training, Aerobic and Resistance Training; Behavioral
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 21 Years and older
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2024
U.S. locations: 1
States / cities: New York, New York

Conditions: Multiple Sclerosis, Relapsing-Remitting
Interventions: Immune Globulin IV [Human], 10% Caprylate/Chromatography Purified, Albumin (Human) 25%, United States Pharmacopeia (USP); Drug
Lead sponsor: Grifols Therapeutics LLC; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 128 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2005
U.S. locations: 6
States / cities: Phoenix, Arizona • Tucson, Arizona • New York, New York + 3 more

Conditions: Aneurysmal Subarachnoid Hemorrhage
Interventions: Cilostazol 100 MG, Placebo; Drug · Other
Lead sponsor: Henry Ford Health System; Other
Eligibility: 18 Years to 100 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Southfield, Michigan

Conditions: Wound Healing
Interventions: SoC Adhesive Bandage, Antibiotic Ointment, Antiseptic Wash, Hydrocolloid Pad; Device · Drug
Lead sponsor: Johnson & Johnson Consumer Inc. (J&JCI); Industry
Eligibility: 25 Years to 55 Years
Enrollment: 34 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Richardson, Texas

Conditions: Gastrointestinal Cancer, Gastrointestinal Neoplasms, Chemotherapy-Induced Thrombocytopenia
Interventions: Avatrombopag, Matching Placebo; Drug
Lead sponsor: Hanny Al-Samkari, MD; Other
Eligibility: 18 Years and older
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 4
States / cities: Miami, Florida • Boston, Massachusetts • Portland, Oregon + 1 more

Conditions: Preclinical Alzheimer's Disease, Prodromal Alzheimer's Disease, Alzheimer Disease
Interventions: AADvac1, Donanemab; Drug
Lead sponsor: Paul S. Aisen; Other
Eligibility: 50 Years to 80 Years
Enrollment: 450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 7
States / cities: Phoenix, Arizona • San Francisco, California • Lexington, Kentucky + 4 more

Conditions: HIV Infections
Interventions: GEO-D03 DNA vaccine, MVA/HIV62B (MVA62B) vaccine, Placebo for GEO-D03 DNA, Placebo for MVA62B:; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2016
U.S. locations: 4
States / cities: Birmingham, Alabama • San Francisco, California • Boston, Massachusetts + 1 more

Conditions: Obesity, Overweight, Diabetes Mellitus, Type 2
Interventions: LY4167586, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 617 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 11
States / cities: Anaheim, California • Los Alamitos, California • Walnut Creek, California + 8 more

Conditions: Hematologic Malignancies, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, Chronic Myelogenous Leukemia, Acute Graft-versus-host Disease
Interventions: ProTmune, Control Arm; Biological
Lead sponsor: Fate Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 15
States / cities: Birmingham, Alabama • Duarte, California • San Diego, California + 12 more

Conditions: Crohn's Disease
Interventions: brivekimig, Placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 99 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 24
States / cities: Fairhope, Alabama • Tucson, Arizona • Escondido, California + 20 more

Conditions: Chemotherapy-induced Nausea and Vomiting
Interventions: GRANISETRON EXTENDED RELEASE INJECTION (GERSC); Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Iron Deficiency Anemia
Interventions: Ferumoxytol, Oral Iron; Drug
Lead sponsor: AMAG Pharmaceuticals, Inc.; Industry
Eligibility: 6 Months to 17 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Waltham, Massachusetts

Conditions: HIV-1-infection
Interventions: ISL/LEN, B/F/TAF, PTM B/F/TAF, PTM ISL/LEN; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 609 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 60
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 50 more

Search by objective public record fields.

Study of Biotene OralBalance Gel for Oral Care in Critically-Ill Mechanically Ventilated Neonates

The Effect of Blood Flow Restriction With and Without Arginine on Physical Performance and Growth Hormone

The Protégé Study - Clinical Trial of MGA031 in Children and Adults With Recent-Onset Type 1 Diabetes Mellitus

A Pivotal Study to Evaluate the Efficacy of Lorundrostat in Subjects With Uncontrolled Hypertension on a Standardized Antihypertensive Medication Regimen

Oral Care Protocol for the Management of Chemotherapy and Radiation Therapy-Induced Oral Mucositis

Ketamine for Endoscopic Sedation in Outpatient Adult Endoscopy.

Efficacy of MBSR Treatment of Cognitive Impairment Among Breast Cancer Survivors

Premedication for Less Invasive Surfactant Administration Study (PRELISA)

A Study to Evaluate Efficacy and Safety of Cabotegravir (CAB) Long Acting (LA) Plus (+) Rilpivirine (RPV) LA Versus BIKTARVY® (BIK) in Participants With Human Immunodeficiency Virus (HIV)-1 Who Are Virologically Suppressed

FST-100 Ophthalmic Suspension in Acute Adenoviral Conjunctivitis

A 16 Weeks Study on Efficacy and Safety of Two Doses of Empagliflozin (BI 10773) (Once Daily Versus Twice Daily) in Patients With Type 2 Diabetes Mellitus and Preexisting Metformin Therapy

Lung Cancer Exercise Training Study

Immune Globulin Intravenous (IGIV) To Treat Relapsing, Remitting Multiple Sclerosis

Cilostazol and Nimodipine Combined Therapy After Aneurysmal Subarachnoid Hemorrhage (aSAH)

A Study to Assess Wound Healing Efficacies of Different Clean, Treat, and Protect Wound Care Regimens Compared to Standard of Care and Untreated

Avatrombopag vs. Placebo for CIT in GI Malignancies

Alzheimer's Tau Platform: Regimen A - AADvac1

Evaluating the Safety and Immune Response of a Prime-Boost HIV Vaccine Regimen in Healthy, HIV-Uninfected, Vaccinia-Naive Adults

A Study of LY4167586 in Participants With Obesity or Overweight With or Without Type 2 Diabetes

Study of ProTmune for Allogeneic HCT in Adult Patients With Hematologic Malignancies

A Study to Investigate Efficacy and Safety of Brivekimig in Participants With Crohn's Disease

Granisetron Extended Release Injection (GERSC) for the Prevention of Chemotherapy-induced Nausea and Vomiting

A Trial of Ferumoxytol for the Treatment of Iron Deficiency Anemia in Pediatric Participants With Chronic Kidney Disease

Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed People With HIV-1